With joint pain adversely affecting more than 80 million Americans, science continues its search for the “perfect” pain reliever. Materials that have the ability to affect the IL-1 Beta inflammatory compound, the COX-2 inflammatory enzyme, and the 5-LO inflammatory pathway are prime targets. For example, Celebrex, the most popular prescription anti-inflammatory, has been shown to selectively inhibit the COX-2 enzyme (but not the 5-LO inflammatory pathway). Glucosamine, a dietary supplement widely used in the treatment of joint pain, is neither a selective COX-2 nor a selective 5-LO inhibitor (although it may have other benefits). Trivestin™, a novel combination of plant extracts, singled out from more than 1,228 carefully screened candidate plants, was selected for its ability to block these established inflammatory enzymes and pathways. Because rigorous laboratory trials confirmed Trivestin’s proficiency in inhibiting gene expression of compounds that cause inflammation, pain, and joint degradation (including IL-1 Beta, COX-2, and 5-LO), it was predicted that Trivestin would not only reduce pain, but also preserve the integrity of joint tissue. To establish Trivestin’s safety and efficacy (and mitigate the subjective nature of pain relief) a clinical trial was designed to compare Trivestin to both placebo and Celebrex, a recognized standard.
WARNINGS: If you are pregnant or lactating, consult a health care professional before using this product. Trivestin should not be consumed by subjects with a history of gastric or duodenal ulcers, subjects on H2 blockers, or subjects on proton pump inhibitors.
30-day, head-to-head, double-blind clinical data were evaluated to compare safety and efficacy of Trivestin to Celebrex. Sixty (60) subjects with confirmed osteoarthritic joint pain were divided equally into four (4) groups: Group 1 – Placebo (sugar pill); Group 2 – Celebrex (200 mg per day); Group 3 – Trivestin (250 mg per day); and Group 4 – Trivestin (500 mg per day). Subjects were instructed to take the prescribed capsules in divided doses twice per day. Improvements in joint pain, mobility, flexibility, stiffness, and ease of motion (“Quality Of Life” parameters) were assessed at 30 days using the standard WOMAC** and SF-36 (Short-Form) evaluations.
Trivestin was shown to be twice as effective as Celebrex (Group 3: p<0.06; Group 4: p<0.05) [over and above placebo, of course] in reducing pain and stiffness, increasing mobility and flexibility, and improving overall quality of life.
The ability of Trivestin to block multiple inflammatory enzymes and pathways (COX-2, IL-1 Beta, and 5-LO) seems to account for Trivestin’s superiority over Celebrex under the conditions of this double-blind, clinical comparative trial.